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ABSTRACT 
 
Background: The current approach to prenatal care, which was established 
more than 80 years ago, is characterised by a high concentration of visits in the 
third-trimester of pregnancy which implies that firstly, most complications occur 
at this late stage of pregnancy and secondly, most adverse outcomes are 
unpredictable during the first or even the second trimester.  
Objectives: The objective of this thesis is to provide evidence that most 
pregnancy complications are predictable as early as 12 weeks’ gestation. The 
pregnancy complications examined include fetal aneuploidies, fetal structural 
defects, preeclampsia, preterm birth, gestational diabetes mellitus and fetal 
macrosomia. 
Methods: I have critically examined fourteen articles reporting on screening for 
pregnancy complications at 11-13 weeks’ gestation, where more than 90,000 
singleton pregnancies were prospectively assessed at 11-13 weeks’ gestation 
as part of a routine prenatal visit for screening for trisomy 21. We recorded a 
series of maternal characteristics and history, measured maternal weight and 
height, performed a detailed ultrasound examination of the fetus, measured 
maternal uterine artery Doppler pulsatility index and maternal mean arterial 
pressure and collected blood for analysis of biomarkers for prospective or 
retrospective analysis. All data were prospectively entered into our data base as 
well as the pregnancy outcomes as soon as they became available. Ethical 
approval was obtained for these studies. Multivariate regression analysis was 
used to define the contribution of each maternal characteristic and history in 
predicting each adverse outcome and those with a significant contribution 
formed an algorithm to estimate the background risk (a priori risk) for each one 
of these complications. The potential value of biophysical and biochemical 
markers in improving the performance of the a priori risk in predicting adverse 
pregnancy outcomes, was evaluated. 
Results: First trimester effective screening for adverse pregnancy outcomes 
was provided by a combination of maternal factors and biophysical or 
biochemical markers. The developed predictive models could correctly identify 
the vast majority of aneuploidies, early preeclampsia and more than half of the 
cases of spontaneous preterm birth and gestational diabetes. First trimester 
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prediction of fetal macrosomia was less effective compared with other 
complications. First trimester examination of fetal anatomy was feasible 
resulting in a high detection of fetal non-chromosomal defects, including more 
than half of fetal cardiac defects.  
Conclusions: Assessment of the mother and fetus at 11-13 weeks’ gestation 
can provide effective early identification of the high risk group of pregnancies 
with fetal and maternal adverse outcomes. 
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CHAPTER 1.  OVERVIEW 
 
1.1 Introduction 
 
This thesis will demonstrate that many serious pregnancy complications are 
detectable or predictable from the 12th week of gestation. In the hospitals where 
I am a research fellow in Fetal Medicine and Honorary Sonographer, all women 
are offered a first trimester assessment where a series of maternal 
characteristics, obstetric and family history are recorded, maternal weight and 
height are measured, a detailed ultrasound examination of the fetus is carried 
out, maternal uterine artery Dopplers and measurement of mean arterial 
pressure are performed and maternal blood is obtained for prospective and/or 
retrospective analysis for various biomarkers. This assessment is carried out by 
a large team of doctors and sonographers, including myself.  
 
Since February 2008, I have been prospectively collecting all these information 
as well as pregnancy outcomes as soon as they became available. I have been 
responsible for the quality assurance of these data, training the doctors and 
sonographers in the ultrasound measurements of the mother and fetus. I have 
been producing individual operator distributions of each ultrasound 
measurement in a regular basis and I was providing further training to those 
whose distribution was incorrect. Furthermore, I have been reviewing with a 
group of other researchers all maternal notes where a pregnancy complication 
was reported to verify the accuracy of the information. Through the guidance of 
Professor Kypros Nicolaides, who is the director of the units where I work and a 
Professor in Fetal Medicine with more than 1,200 publications in peer-review 
international scientific journals, I learnt how to define a research question, apply 
the research methodology, obtain ethical approval, and conduct a research 
study assuring high quality of data. I have also been working closely with 
Professor David Wright, a Professor in Statistics, who helped me to understand 
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statistics and taught me how to conduct a statistical analysis. After collecting 
thousands of data we came to realize that actually there is a strong relationship 
with most of maternal factors, biophysical and biochemical markers examined at 
11-13 weeks’ gestation with subsequent adverse fetal and maternal outcomes 
and this is exactly what this thesis is highlighting.        
 
A first trimester visit can become the basis of a more individualised care where 
every woman will be assessed and a risk for each pregnancy complication can 
be calculated. The vast majority of women would be provided with a low risk 
and these can follow routine antenatal care. A few women that have a high-risk 
for complications will be directed to a more specialized pathway with close 
surveillance, where early therapeutic interventions may lead to the prevention of 
the disease or detection at the early stages of the disease so that adverse 
consequences can be prevented. 
 
This thesis will stimulate other researchers to expand the number of conditions 
that can be identified in early pregnancy and investigate new biophysical and 
biochemical markers that will improve the accuracy of the a priori risk based on 
maternal characteristics, medical and obstetric history. Moreover, early 
identification of high-risk groups will stimulate further research that will define 
the best management plans and develop new strategies for the prevention of 
disorders.  
 
1.2 Early screening for aneuploidies 
 
Aneuploidies are major causes of perinatal death and childhood handicap. The 
prenatal detection of aneuploidies relies on invasive testing, such 
amniocentesis or chorionic villus sampling (CVS), which is associated with a 
risk of miscarriage and therefore these tests are carried out only in pregnancies 
considered to be at high-risk. In the last 40 years prenatal screening for 
aneuploidies has focused on trisomy 21. The method of screening has evolved 
from maternal age in the 1970’s, with detection rate (DR) of trisomy 21 of 30%, 
to a combination of maternal age and second-trimester serum biochemistry in 
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the 1980s and 1990s, with DR of 60-70% (Wald 2003, Malone 2005). In the last 
20 years, the combination of maternal age, fetal nuchal translucency thickness 
(NT), serum free β-human chorionic gonadotropin (β-hCG) and pregnancy-
associated plasma protein A (PAPP-A) has increased the DR to 90% at a false 
positive rate (FPR) of 5% (Nicolaides 1992, Brizot 1994, Snijders 1998, Bindra 
2002, Kagan 2008, Wright 2010). A beneficial consequence of screening for 
trisomy 21 is the early diagnosis of trisomies 18 and 13, which are the second 
and third most common chromosomal abnormalities, with a relative prevalence 
to trisomy 21 at 11-13 weeks’ gestation of 1:3 and 1:7, respectively (Snijders 
1994, 1995).  
 
Studies in the last 10 years have shown that improvement in the performance of 
first-trimester screening can be achieved by firstly, the inclusion in the 
ultrasound examination the assessment of the nasal bone, flow in the ductus 
venosus and across the tricuspid valve (Cicero 2001, 2006, Maiz 2009, Huggon 
2003, Kagan 2009), secondly, inclusion of maternal serum placental growth 
factor (PLGF) and α-fetoprotein (AFP) in the biochemical assessment (Pandya 
2012, Bredaki 2011) and thirdly analysis of cell-free (cf) DNA in maternal blood.  
 
In Chapter 2, I have included four publications; the first one demonstrates how 
the performance of screening for trisomies 21, 18 and 13 can be further 
improved by the addition of other ultrasound and biochemical markers. The 
second publication examines the performance of cfDNA testing in maternal 
blood in screening for these aneuploidies in a routine population undergoing 
screening for trisomies 21, 18 and 13 at 11-13 weeks’ gestation. The third 
publication examines the performance of screening for trisomies by an 
approach which combines the traditional method of screening with cfDNA 
testing. In the fourth publication we investigate the proportion of other 
chromosomal abnormalities that could be missed if combined testing was 
replaced by cfDNA testing as the method of screening for trisomies 21, 18 and 
13. 
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1.21 First trimester screening for trisomies 21, 18 and 13 by 
ultrasound and biochemical testing 
 
In this paper we examined the performance of screening for trisomies 21, 18 
and 13 at 11-13 weeks’ gestation using specific algorithms based on 
combinations of maternal age, gestational age, fetal NT, fetal heart rate (FHR), 
ductus venosus pulsatility index for veins (DV PI), and maternal serum free β-
hCG, PAPP-A, PLGF and AFP. This model could detect 93.3% of trisomy 21 
cases and 95.4% for trisomies 18 and 13 at a FPR of 1.3% (Wright 2014).  
 
Strengths and limitations 
 
We derived data for NT, FHR and DV PIV from more than 85,000 prospectively 
screened pregnancies and serum free ß-hCG and PAPP-A from more than 
70,000 pregnancies. These included more than 300 cases of trisomy 21 and 
more than 100 cases of trisomy 18, but only 39 of trisomy 13. The study 
population for PLGF was more than 25,000, including 138 cases of trisomy 21, 
53 of trisomy 18 but only 11 of trisomy 13. For AFP we examined less than 
10,000 pregnancies and only 65 cases of trisomy 21, 18 of trisomy 18 and 14 of 
trisomy 13. Consequently, because of the relatively limited data available, the 
modelled measures of screening performance are subject to a high degree of 
uncertainty due to sampling and non-sampling errors that are not easily 
quantified. However, the consistency between the modelled and empirical rates 
was reassuring.   
 
1.22 Non-invasive prenatal testing for fetal trisomies in a 
routinely screened first-trimester population 
 
In this paper, we investigated the performance of non-invasive prenatal testing 
(NIPT) by analysis of cfDNA in maternal blood in detecting fetal trisomies in a 
routinely screened population undergoing routine screening for aneuploidies at 
11-13 weeks’ gestation. We found that the performance of screening for trisomy 
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21 and trisomy 18 by NIPT using chromosome-selective sequencing in a routine 
population is effective with DR of >99% and FPR <1% (Nicolaides 2012).  
 
Strengths and limitations 
 
The study population of 2,049 singleton pregnancies was derived from women 
undergoing first-trimester screening for aneuploidies as part of their routine 
antenatal care in an inner city maternity hospital. The observed number of 
trisomies was as expected on the basis of the maternal age distribution of the 
study population, which was similar to the national average in England, UK 
(Office for National Statistics 2010). 
 
A limitation of the study was that we did not perform karyotyping in all cases 
and the assumption of euploidy was based on the lack of phenotypic features of 
aneuploidy in the neonates. This was an inevitable consequence of the nature 
of the study which was based on a population undergoing routine screening for 
aneuploidies, rather than a high-risk population undergoing invasive testing.  
 
1.23 First-trimester contingent screening for trisomies 21, 18 
and 13 by biomarkers and maternal blood cell-free DNA testing 
 
In the third paper we examined the performance of screening for trisomies by 
an approach which combines the traditional method of screening with cfDNA 
testing. We explored the consequences of screening for aneuploidies by two 
strategies; first-line screening by cfDNA testing and cfDNA testing contingent on 
the results of combined ultrasound and serum biochemistry. We proposed that 
cfDNA testing in maternal blood should be offered on the basis of the results of 
first-line testing by combinations of NT, FHR, DV PIV, and maternal serum β-
hCG, PAPP-A, PLGF and AFP (Nicolaides 2014).  
 
Strengths and limitations 
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The strategy of cfDNA testing contingent on the results of combined ultrasound 
and serum biochemistry can substantially improve the performance of screening 
but also retain the advantages of the combined test which include firstly, 
diagnosis of aneuploidies within the first trimester with the option for earlier and 
safer termination of pregnancy, and secondly, early detection of major defects 
and prediction of a wide range of pregnancy complications which allows for 
earlier therapeutic intervention and better pregnancy management. 
 
The limitation of this study is that the estimates on performance of screening by 
cfDNA were based on a series of assumptions. The first assumption was that 
cfDNA testing can detect 99.5% of cases of trisomy 21, 98% of trisomy 18 and 
92% of trisomy 13, with respective FPRs of 0.1%, 0.1% and 0.3%. These are 
the summary values of published studies which mainly examined high-risk 
pregnancies (Gil 2014). The second assumption is that the failure rate of cfDNA 
testing to provide a result is 5%. This is based on our finding from clinical 
implementation of cfDNA testing at 10 weeks’ gestation (Gil 2013). The third 
assumption is that invasive testing is carried out in firstly, those with a positive 
result from cfDNA testing and secondly, those where cfDNA testing fails to give 
a risk for trisomies and the combined test risk is 1:100 or higher. However, in 
practice it is likely that some women in the low-risk group from cfDNA testing 
would still desire to have a diagnostic test to provide certainty of exclusion of 
trisomies 21, 18 and 13 but also of other aneuploidies. This is particularly 
important in cases with fetal abnormalities and those with high NT. 
 
1.24 Replacing the combined test by cell-free DNA testing in 
screening for trisomies 21, 18 and 13: impact on the diagnosis 
of other chromosomal abnormalities 
 
In this paper we investigated the proportion of other chromosomal abnormalities 
that could be missed if combined testing was replaced by cfDNA testing as the 
method of screening for trisomies 21, 18 and 13. The prevalence of trisomies 
21, 18 or 13, sex chromosome aneuploidies, triploidy and other chromosomal 
abnormalities was examined in pregnancies undergoing first-trimester combined 
CHAPTER I 
 
13 
 
screening and CVS. This study in pregnancies undergoing CVS for fetal 
karyotyping after first trimester combined screening for trisomies 21, 18 and 13 
has demonstrated three findings. Firstly, trisomies 21, 18 and 13 account for 
about 80% of the detected clinically significant chromosomal abnormalities. 
Secondly, the distribution of some or all marker levels, including maternal age, 
fetal NT, FHR and serum free ß-hCG and PAPP-A, in the various abnormalities 
are significantly different from those in the normal pregnancies. Thirdly, the 
prevalence of trisomies 21, 18 and 13, monosomy X, triploidy and other 
abnormalities at high-risk of adverse outcome is higher in the group with 
estimated risk for trisomies 21, 18 or 13 of >1:100, compared to those with risk 
of <1:100, and in those with fetal NT >3.5 mm, compared to those with NT<3.5 
mm. Consequently, these aneuploidies are preselected, to varying degrees, by 
the first trimester combined test. Screening by cfDNA testing, contingent on 
results of combined testing, improves detection of trisomies, but misses a few of 
the other chromosomal abnormalities detected by screening with the combined 
test (Syngelaki 2014). 
 
Strengths and limitations 
 
The main strength of this study is the large number of pregnancies examined. 
We used data from 14,684 singleton pregnancies undergoing invasive test for 
fetal karyotyping and 74,561 singleton pregnancies undergoing routine 
screening for aneuploidies with combined testing. The main limitation of our 
screening study relates to ascertainment of pregnancy outcome, especially for 
the group classified as euploid, which was essentially based on the absence of 
any suspicious clinical findings in the neonatal period. In the case of sex 
chromosome aneuploidies we estimated the potential impact of such 
ascertainment bias. However, in the case of other abnormalities, both for those 
at high-risk of adverse outcome and more so for those at low-risk, it is 
impossible in the absence of karyotyping all neonates to define their true 
prevalence and it is likely that this has been considerably underestimated and 
the ability of the combined test to detect them has been overestimated. The 
estimates we derived on the prevalence of other chromosomal abnormalities at 
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high-risk of adverse outcome are based on assumptions that will be difficult to 
validate. 
 
1.3 Early screening for fetal defects 
 
Fetal non-chromosomal structural defects are the most common cause of 
perinatal mortality. Cardiac defects account for about 20% of all stillbirths and 
30% of neonatal deaths (Office for National Statistics 2007). In the United 
Kingdom, the National Institute for Clinical Excellence (NICE) has issued 
guidelines on routine antenatal care recommending that pregnant women 
should be offered two ultrasound scans in pregnancy (NICE 2008).  
 
The primary aims of the first scan at 11-13 weeks are to establish gestational 
age from the measurement of fetal crown-rump length (CRL), to detect multiple 
pregnancies and determine chorionicity and to measure fetal nuchal 
translucency (NT) thickness as part of combined screening for trisomy 21. The 
primary aim of the second scan, which is carried out at about 20 weeks, is the 
detection of structural fetal abnormalities. With this approach, the vast majority 
of fetal detects are detected only in the second trimester of pregnancy.   
 
In Chapter 3, I have included three publications which aimed to define the 
performance of the 11-13 weeks scan in detecting fetal non-chromosomal 
abnormalities and secondly, to demonstrate how the detection rate of major 
cardiac defects can be improved by the examination of the blood flow in the 
tricuspid valve and ductus venosus after assessing a population of >45,000 
singleton pregnancies.   
 
This is particularly important as the current method of screening for cardiac 
defects, which relies on family history of such defects, maternal history of 
diabetes mellitus and maternal exposure to teratogens can identify only about 
10% of affected fetuses (Allan 1995).  
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1.31 Challenges in the diagnosis of fetal non-chromosomal 
abnormalities at 11-13 weeks 
 
In this paper, we examined the performance of the 11-13 weeks scan in 
detecting non-chromosomal abnormalities. This was a prospective study were 
the findings were compared to those of the 20-23 weeks scan and postnatal 
examination. We concluded that at 11-13 weeks some abnormalities are always 
detectable, some can never be and others are potentially detectable depending 
on their association with increased NT, the phenotypic expression of the 
abnormality with gestation and the objectives set for such a scan (Syngelaki 
2011).  
 
Strengths and limitations 
 
The strengths of this study were the large number of pregnancies examined, the 
specific check list used for the ultrasound examination of fetal anatomy and that 
the sonographers had received appropriate training to perform such 
examination.  
 
This was the largest study is the literature to describe the performance of the 
11-13 weeks’ scan in detecting structural defects in a low risk population. The 
vast majority of previous publications reporting on the detection rate of fetal 
defects at this gestation were in a small group of high risk pregnancies and this 
could not allow a fair comparison of our results with these studies. 
    
1.32 Contribution of ductus venosus Doppler in first trimester 
screening for major cardiac defects 
 
In this paper, we determined whether assessment of ductus venosus (DV) flow 
at 11-13 weeks' gestation improves the detection rate of cardiac defects 
achieved by screening with fetal NT thickness. We found that reversed flow in 
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the DV is common among fetuses with cardiac defects and assessment of DV 
flow improves the performance of NT screening (Cheleman 2011).  
 
Strengths and limitations 
 
The strengths of this study are that we examined a large population of singleton 
pregnancies, including 85 with major fetal cardiac defects. Furthermore, all 
operators had received extensive training for the measurement of fetal NT and 
assessment of DV and had obtained certifications of competence in doing so.  
  
A limitation of this study was that in all live births the diagnosis of cardiac 
defects was based on clinical examination only in the neonatal period. It is 
therefore likely that some defects, such as coarctation of the aorta and 
transposition of the great arteries, the diagnosis may have been missed. 
Another limitation of this study is the method of diagnosing or excluding a 
cardiac defect in cases of pregnancy termination or fetal death. We selected the 
pragmatic end-point of sonographically detectable defect by a paediatric 
cardiologist specialist in fetal echocardiography. Ideally in these cases the 
antenatal findings should have been validated by post-mortem examination but 
this was not performed in all cases.  
 
1.33 Contribution of fetal tricuspid regurgitation in first 
trimester screening for major cardiac defects 
 
In this paper, we investigated the potential value of assessment of the blood 
flow across the fetal tricuspid valve in the prediction of major cardiac defects at 
11-13 weeks’ gestation. We used the same population as the previous paper 
and we found that tricuspid regurgitation is very common in fetuses with major 
cardiac defects at 11-13 weeks’ gestation and this assessment improves the 
detection rate of these abnormalities when combined with the measurement of 
NT thickness and assessment of the DV flow. For fixed FPRs of 1%, 3% and 
5%, the estimated DRs of major cardiac defects in screening by fetal NT alone 
were 25.9%, 30.6% and 35.3%, respectively, and these were increased to 
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36.5%, 48.2% and 54.1%, respectively, in screening by a combination of NT 
and both ductus venosus and tricuspid flow (Pereira 2011). 
 
Strengths and limitations 
 
The strength if the study is that we developed an algorithm combining fetal NT 
with flow in the DV and across the tricuspid valve to estimate the patient-
specific risk for major cardiac defects. The use of specific risk cut-offs which will 
depend on available resources and clinics will direct patient to specialists in 
fetal echocardiography which will allow an early detection of major cardiac 
defects. 
 
The potential limitations of this study are the same as the previous publication 
examining the contribution of DV assessment in screening for major cardiac 
defects at 11-13 weeks’ gestation (Cheleman 2011). 
 
1.4 Early screening for preeclampsia 
 
Preeclampsia (PE) is a major cause of maternal and perinatal morbidity and 
mortality affecting 2-3% of all pregnancies (WHO 2005, CEMACH 2008, Duley 
2009). In the last decade extensive research has been devoted to screening for 
PE with the aims of firstly, reducing the prevalence of the disease through 
pharmacological intervention in the high-risk group (Bujold 2010, Roberge 
2012) and secondly, minimizing adverse perinatal events for those that develop 
PE by determining the appropriate time and place for delivery (Koopmans 
2009).  
 
The traditional approach to screening for PE is to identify risk factors from 
maternal demographic characteristics and medical history. In the UK, the 
National Institute for Health and Clinical Excellence (NICE) has issued 
guidelines recommending that women should be considered to be at high-risk of 
developing PE if they have any one high-risk factor or any two moderate-risk 
factors (NICE 2010). However, the performance of such approach, which 
OVERVIEW 
18 
 
essentially treats each risk factor as a separate screening test, has a screen 
positive rate of 11.2% and the DRs of all PE, PE requiring delivery at <37 and at 
<34 weeks’ gestation are 35%, 40% and 44%, respectively (Wright 2015). In 
chapter four, I have included three papers which essentially demonstrate 
effective methods of screening for PE from as early as 12 weeks’ gestation. 
Early identification of the high-risk group for subsequent development of PE can 
potentially improve outcome by directing such patients to specialist clinics for 
close surveillance.  
 
1.41 Prediction of early, intermediate and late preeclampsia 
from maternal factors, biophysical and biochemical markers at 
11-13 weeks 
 
In this paper, we developed models for the prediction of early PE, requiring 
delivery before 34 weeks, intermediate PE with delivery at 34-37 
weeks and late PE delivering after 37 weeks. These models were based on 
maternal factors, biophysical and biochemical markers at 11-13 weeks’ 
gestation. The performance of these models was effective with estimated DRs 
of 91.0% for early PE, 79.4% for intermediate PE and 60.0% for late PE, at a 
fixed FPR of 5% (Akolekar 2011). 
 
Strengths and limitations 
 
The main strengths of this study were firstly the large number of pregnancies 
examined prospectively in a narrow gestation range between 11-13 weeks’ 
gestation and secondly, the use of logistic regression analysis to derive the a 
priori risk for each of the PE groups from maternal characteristics. In this model, 
maternal characteristics and history were incorporated into a combined 
algorithm derived by multivariate analysis and the effects of variables were 
expressed as odds ratios for early, intermediate and late PE. This alternative 
method of screening of PE is superior than the one proposed by NICE as it has 
a higher detection rate and most importantly can provide women a patient-
specific risk for PE. The limitation of this study was that the gestational age at 
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delivery in the case of PE was treated as a categorical variable rather than a 
continuous.  
 
1.42 A competing risks model in early screening for 
preeclampsia 
 
In this paper, we developed a survival time model for the prediction of PE in 
which the gestation at the time of delivery for PE was treated as a continuous 
variable. We used maternal characteristics and biophysical markers, including 
uterine artery pulsatility index (PI) and mean arterial pressure (MAP) at 11-13 
weeks' gestation. The Bayes' theorem was used to combine the prior 
information from maternal characteristics with the uterine artery PI and the 
MAP. We found that screening by maternal characteristics, uterine artery PI and 
MAP can detect 90% of PE cases requiring delivery before 37 weeks and 57% 
of all PE cases at a fixed FPR of 10% (Wright 2012).  
 
Strengths and limitations 
 
This study demonstrated that PE is a spectrum disorder the degree of which is 
reflected in gestational age at the time of delivery, rather than considering PE 
as two or three different diseases. Multivariate screening for PE with maternal 
risk factors evolved into a new approach in which the gestation at the time of 
delivery for PE was treated as a continuous rather than a categorical variable. 
The major strengths of the study were firstly, prospective examination of a large 
number of pregnancies in which specific questions were asked to identify known 
factors associated with PE, secondly, the use of multivariable survival analysis 
to identify the factors and define their contribution in the prediction of PE and 
thirdly, the development of a survival-time model which allowed estimation of 
individual patient-specific risks of PE requiring delivery before any specified 
gestation. Bayes theorem was used to combine the information on maternal 
characteristics and medical history with biomarkers for risk assessment at 
different stages of pregnancy. A limitation of the study was that the performance 
of screening by a model derived and tested using the same dataset could be 
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overestimated and a cross validation to reduce this effect was not performed. 
Furthermore, external validation on independent data from different sources will 
be required to confirm these results. 
 
1.43 Competing risks model in early screening for preeclampsia 
by biophysical and biochemical markers 
 
In this paper, we developed a model for the prediction of PE based on maternal 
characteristics, biophysical and biochemical markers, including PAPP-A and 
PLGF at 11-13 weeks' gestation in which the gestation at the time of delivery for 
PE is treated as a continuous variable. We found that screening by this 
combination can achieve a DR of 96% of cases of PE requiring delivery before 
37 weeks and 54% of all cases of PE at a fixed FPR of 10% (Akolekar 2013).  
 
Strengths and limitations 
 
The strengths and limitations of this study are the same as the one of Akolekar 
2013. 
 
1.5 Early screening for preterm birth 
 
Preterm birth is responsible for more than 70% of all neonatal and infant deaths 
(Office for National Statistics 2012). Additionally, children born preterm, 
compared to those born at term, have a 10-fold increase in risk of cerebral palsy 
(Kodjebacheva 2015). Mortality and morbidity are inversely related to 
gestational age at delivery and are therefore more common in cases with early 
preterm birth (Office for National Statistics 2012, Saigal 2008, D'Onofrio 2013). 
The risk of preterm birth is inversely related to cervical length measured by 
ultrasound examination at mid-gestation (Iams 1996). 
 
The rate of preterm birth has not decreased in the last 30 years (Goldenberg 
2008). Although improvements in neonatal care have led to higher survival of 
CHAPTER I 
 
21 
 
very premature infants, a major impact on the associated mortality and 
morbidity will only be achieved through the development of a sensitive method 
to identify women at high-risk of preterm delivery and an effective strategy for 
prevention of this complication. 
 
In Chapter 5, I included two publications which illustrate methods of identifying 
women being at high risk for early preterm birth. These studies have provided 
evidence that spontaneous preterm delivery can be effectively identified by 
screening at 11-13 weeks’ gestation and ongoing randomized studies, based on 
first-trimester screening to identify the high-risk group for subsequent early 
delivery, will investigate the extent to which pregnancy outcome would improve 
through early intervention with such measures as prophylactic use of 
progesterone. 
 
1.51 Prediction of spontaneous preterm delivery from maternal 
factors, obstetric history and placental perfusion and function 
at 11-13 weeks 
 
In this paper, we developed a model for the prediction of spontaneous delivery 
before 34 weeks’ gestation based on maternal factors and markers of 
placental perfusion and function at 11-13 weeks' gestation. We examined 
34,390 singleton pregnancies in a prospective manner, including 365 cases that 
delivered spontaneously before 34 weeks of gestation. This model could identify 
correctly 38.2% of the preterm deliveries in women with previous pregnancies at 
or beyond 16 weeks and 18.4% in those without, at a FPR of 10% (Beta 2011).  
 
Strengths and limitations 
 
The main strengths of this study were firstly the large number of pregnancies 
examined, secondly the well documented maternal characteristics and 
outcomes, and thirdly, the use of multivariable logistic regression analysis to 
identify the factors associated with preterm birth which provided a patient 
specific risk for this condition.  
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The rate of spontaneous preterm delivery before 34 weeks in a heterogeneous 
inner city population was 1% and in half of the cases there was spontaneous 
onset of labor and in the other half there was preterm pre-labor rupture of 
membranes. These rates are similar to those in our previous multicentre study 
of about 60,000 singleton pregnancies involving hospitals in and around London 
(Celik 2008). 
 
A potential limitation of the study was that cases with prenatal interventions for 
preterm birth such prophylactic cerclage or administration of progesterone 
because of previous preterm birth or short cervical length, were not examined 
separately. It is known that these interventions are effective and the inclusion of 
these cases in the control group may have led to an underestimation of the 
detection rate of our model.  
 
1.52 First trimester screening for spontaneous preterm delivery 
with maternal characteristics and cervical length 
 
In this paper, we examined the potential value of cervical length at 11-13 weeks 
of gestation in the prediction of spontaneous preterm delivery before 34 weeks 
of gestation. We examined 9,974 singleton pregnancies including 104 (1.0%) 
cases that delivered prematurely. We used multiple regression analysis to 
determine the value of cervical length over and above the maternal 
characteristics and obstetric history. This study demonstrated that in screening 
by a combination of maternal characteristics and cervical length, the estimated 
DR of preterm delivery was 54.8%, at a FPR of 10% (Greco 2011). 
 
Strengths and limitations 
 
This was the largest study evaluating cervical length at 11-13 weeks’ gestation 
in predicting spontaneous preterm birth. Furthermore, cervical length was 
measured by operators who had received specific training in undertaking such 
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measurement and they had obtained a certification of competence in measuring 
cervical length, which ensured the reliability of data. 
 
1.6 Early screening for gestational diabetes mellitus and 
macrosomia  
 
Gestational diabetes mellitus (GDM) is associated with increased risk of 
maternal and perinatal short-term and long-term complications (Casey 1997, 
Metzger 2008, Clausen 2008, Reece 2010, Feig 2008, Bellamy 2009). The 
condition is diagnosed by a positive oral glucose tolerance test, which is usually 
carried out in the late second trimester of pregnancy either in all pregnant 
women (Metzger 2010) or in a selected group of women identified by their 
demographic characteristics and obstetric history as being at high risk for GDM 
(NICE 2008). Consequently, diagnosis and treatment of affected pregnancies 
occur during the late second or early third trimester of pregnancy. Such late 
onset of treatment reduces but does not eliminate the excess risks of 
associated complications (Hammoud 2013, Crowther 2005, Landon 2009).  
 
In contrast, effective early identification of the high-risk group for subsequent 
development of GDM is likely to have a greater impact in improving pregnancy 
outcome because with appropriate dietary advice and pharmacological 
interventions the incidence of the disease could potentially be reduced. 
 
Fetal macrosomia is associated with increased risks for the mother, including 
caesarean section and trauma to the birth canal, and for the baby, including 
shoulder dystocia and consequent brachial plexus or facial nerve injuries, 
fractures of the humerus or clavicle and birth asphyxia (Ferber 2000, Grassi 
2000, Henriksen 2008). In chapter 6, I have included 2 papers which describe 
models for the prediction of GDM and fetal macrosomia from maternal 
characteristics and biochemical markers at 11-13 weeks’ gestation. The extent 
to which the performance of early screening for GDM and fetal macrosomia can 
be further improved by additional biomarkers is currently under investigation.  
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1.61 Prediction of gestational diabetes mellitus by maternal 
factors and biomarkers at 11-13 weeks 
 
In this paper, we developed a model for the prediction of GDM 
from maternal characteristics and biochemical markers at 11 to 13 weeks' 
gestation in a prospective screening population. In addition, we measured 
maternal serum concentrations of adiponectin, follistatin-like-3 and sex 
hormone-binding globulin (SHBG) in a case-control study. We found that in 
screening for GDM by maternal characteristics, the DR was 61.6% at a FPR of 
20% and the detection increased to 74.1% by the addition of adiponectin and 
SHBG (Nanda 2011).  
 
Strengths and limitations 
 
The main strengths of this study were firstly the large number of pregnancies 
examined, secondly the well documented maternal characteristics and 
outcomes, and thirdly, the use of multivariable logistic regression analysis to 
identify the factors associated with GDM which provided a patient specific risk 
for the development of the disease. 
 
The main limitation of this study relates to the method of identifying the GDM 
affected pregnancies. The diagnostic OGTT was not carried out in all 
pregnancies, as recommended by the international association of diabetes and 
pregnancy study groups (Crowther 2005), but only in those with abnormal 
results of a random blood glucose level at 24-28 weeks’ gestation. If some of 
the women included in our normal group actually had GDM, the performance of 
screening of our method was underestimated.  
 
1.62 First-trimester prediction of macrosomia 
 
In this paper, we explored the potential value of the parameters used in 
screening for aneuploidies at 11-13 weeks, combined with maternal 
characteristics, in providing significant prediction of macrosomia. We used 
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multiple regression analysis to determine the significant contributors. We found 
that screening for macrosomia by a combination of maternal characteristics and 
obstetric history with fetal nuchal translucency, and maternal serum free ß-hCG 
and PAPP-A at 11-13 weeks could potentially identify about 35% of women who 
will deliver macrosomic neonates, at a FPR of 10%. The detection rate was 
further improved to about 40% by the measurement of maternal serum 
adiponectin concentration at 11-13 weeks’ gestation (Poon 2011). 
 
Strengths and limitations  
 
The main strengths of this study were firstly the large number of pregnancies 
examined, secondly the well documented maternal characteristics and 
outcomes, and thirdly, the use of multivariable logistic regression analysis to 
identify the factors associated with fetal macrosomia which provided a patient 
specific risk for this condition. 
 
The performance of early screening for macrosomia was poor compared to that 
of screening for aneuploidies and preeclampsia. Similarly, the extent to which 
knowledge of the individual patient-specific risk for macrosomia by first-trimester 
combined screening can improve antenatal surveillance and prevention of 
macrosomia itself or the intrapartum complications related to macrosomia 
remains to be determined by future studies. 
 
The next Chapter will address screening for aneuploidies at 11-13 week’s 
gestation by the combined test and cfDNA test and will examine the 
performance and implications of each test.  
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CHAPTER 2.  EARLY SCREENING FOR 
ANEUPLOIDIES 
 
This chapter is based on four publications. The first one examines additional 
markers in screening for trisomies 21, 18 and 13 and their impact in the 
performance of screening. The second publication examines the performance of 
cell free (cf) DNA testing in maternal blood in screening for aneuploidies in a routine 
screening population. The third publication examines the performance of screening 
for trisomies by an approach which combines the traditional method of screening 
with cfDNA testing. In the fourth publication we investigate the proportion of other 
chromosomal abnormalities that could be missed if combined testing was replaced 
by cfDNA testing as the method of screening for trisomies 21, 18 and 13. 
 
Several studies published prior to the publications included in this thesis, reported on 
cfDNA testing in screening for trisomies 21, 18 and 13 but these were limited in high 
risk pregnancies. Our study was the first to examine cfDNA testing in screening for 
trisomies 21, 18 and 13 in low risk population prospectively. Based on our results, 
we went further to explore possible implementation strategies and their implications 
on the performance in of screening for aneuploidies. Furthermore, in our hospitals, 
we are now conducting a prospective research study with an aim to identify factors 
that can influence the decision of women undergoing combined screening in favor of 
or against CVS and in favor of or against cfDNA testing. 
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13 by biomarkers and maternal blood cell-free DNA testing. Fetal Diagn Ther 
2014;35:185-92. 
 
http://www.ncbi.nlm.nih.gov/pubmed/24525399 Syngelaki A, Pergament E, 
Homfray T, Akolekar R, Nicolaides KH. Replacing the combined test by cell-free 
DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of 
other chromosomal abnormalities. Fetal Diagn Ther 2014;35:174-84.  
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The next Chapter will address screening for fetal non-chromosomal abnormalities at 
11-13 weeks’ gestation by an ultrasound examination. The performance of this vist 
in detecting stractural defects will be defined and the potential role of ultrasound 
markers of fetal circulation will be examined in improving screening for major 
cardiac defects.  
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CHAPTER 3.  EARLY SCREENING FOR 
FETAL DEFECTS 
 
This chapter is based on three publications. The first publication demonstrates that 
the 11-13 weeks scan can identify many non-chromosomal major abnormalities, 
but the performance for most abnormalities ultimately depends on their association 
with easily detectable markers, on a policy decision as to the objectives of the scan 
and the necessary allocation of resources for achieving such objectives. The other 
two publications investigate whether the assessment of the flow across the 
tricuspid valve and the ductus venosous at 11-13 weeks, can improve the 
performance of screening for fetal cardiac defects.   
 
The 11-13 weeks scan evolved over the last 20 years from essentially a scan for 
measurement of fetal nuchal translucency and crown-rump length to one which 
includes a basic checklist for examination of the fetal anatomy with the intention of 
diagnosing major abnormalities. An advantage of early rather than late diagnosis of 
major abnormalities, which are either lethal or associated with severe handicap, is 
that the parents are provided with the option of earlier and safer pregnancy 
termination. 
 
 
Publications 
 
http://www.ncbi.nlm.nih.gov/pubmed/21210483 Syngelaki A, Chelemen T, Dagklis 
T, Allan L, Nicolaides KH. Challenges in the diagnosis of fetal non-chromosomal 
abnormalities at 11-13 weeks. Prenat Diagn 2011;31:90-102. 
 
http://www.ncbi.nlm.nih.gov/pubmed/21160164 Chelemen T, Syngelaki A, Maiz N, 
Allan L, Nicolaides KH. Contribution of ductus venosus Doppler in first-trimester 
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screening for major cardiac defects. Fetal Diagn Ther 2011;29:127-34. 
 
http://www.ncbi.nlm.nih.gov/pubmed/21606749 Pereira S, Ganapathy R, Syngelaki 
A, Maiz N, Nicolaides KH. Contribution of fetal tricuspid regurgitation in first-
trimester screening for major cardiac defects. Obstet Gynecol 2011;117:1384-91. 
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The next Chapter will address screening for spontaneous preterm birth at 11-13 
weeks’ gestation by a combination of maternal factors, biochemical markers and 
cervical lenght. 
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CHAPTER  4.  EARLY SCREENING FOR 
PREECLAMPSIA 
 
This chapter is based on three publications. Preeclampsia (PE), which affects 
2-3% of pregnancies, is a major cause of maternal and perinatal morbidity and 
mortality. There is evolving evidence that both the degree of impaired 
placentation and the incidence of adverse fetal and maternal short-term and 
long-term consequences of preeclampsia are inversely related to the gestational 
age at onset of the disease. 
 
In the first paper, we developed models for the prediction of early PE, requiring 
delivery before 34 weeks, intermediate PE with delivery at 34-37 
weeks and late PE delivering after 37 weeks based on maternal factors, 
biophysical and biochemical markers at 11-13 weeks’ gestation. In the second 
paper, we developed a survival time model for the prediction of PE in which the 
gestation at the time of delivery for PE is treated as a continuous variable. We 
used maternal characteristics and biophysical markers at 11-13 weeks' 
gestation. The Bayes' theorem was used to combine the prior information from 
maternal characteristics with the biophysical markers. Similarly, in the third 
paper, we developed a model for the prediction of PE which included all the 
factors from paper two and biochemical markers measured prospectively in a 
large population.  
 
 
Publications 
 
http://www.ncbi.nlm.nih.gov/pubmed/21210481 Akolekar R, Syngelaki A, 
Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late 
pre-eclampsia from maternal factors, biophysical and biochemical markers at 
11-13 weeks. Prenat Diagn 2011;31:66-74. 
 
http://www.ncbi.nlm.nih.gov/pubmed/22846473 Wright D, Akolekar R, Syngelaki 
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A, Poon LC, Nicolaides KH. A competing risks model in early screening for 
preeclampsia. Fetal Diagn Ther. 2012;32:171-8. 
 
http://www.ncbi.nlm.nih.gov/pubmed/22906914 Akolekar R, Syngelaki A, Poon L, 
Wright D, Nicolaides KH. Competing risks model in early screening for 
preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 
2013;33:8-15. 
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The next Chapter will address screening for preeclampsia at 11-13 weeks’ 
gestation by a combination of maternal factors, biophysical and biochemical 
markers.  
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CHAPTER 5.  EARLY SCREENING FOR 
PRETERM DELIVERY 
 
This chapter is based on two publications. Preterm birth is the leading cause of 
perinatal death and handicap in children and the vast majority of mortality and 
morbidity relates to early delivery before 34 weeks. Delivery before 34 weeks 
occurs in about 2% of singleton pregnancies. In two-thirds of the cases this is due 
to spontaneous onset of labour or preterm pre-labour rupture of membranes and in 
the other one-third it is iatrogenic. Although improvements in neonatal care have 
led to higher survival of very premature infants, a major impact on the associated 
mortality and morbidity will only be achieved through the development of a 
sensitive method to identify women at high-risk of preterm delivery and an effective 
strategy for prevention of this complication.  
 
In the first paper, we developed a model for the prediction of spontaneous delivery 
before 34 weeks of gestation based on maternal factors and markers of 
placental perfusion and function at 11-13 weeks' gestation. In the second paper, 
we examined the potential value of cervical length at 11-13 weeks of gestation in 
the prediction of spontaneous preterm delivery before 34 weeks of gestation.  
 
Publications 
http://www.ncbi.nlm.nih.gov/pubmed/21210482 Beta J, Akolekar R, Ventura W, 
Syngelaki A, Nicolaides KH. Prediction of spontaneous preterm delivery from 
maternal factors, obstetric history and placental perfusion and function at 11-13 
weeks. Prenat Diagn 2011;31:75-83. 
 
http://www.ncbi.nlm.nih.gov/pubmed/22399065 Greco E, Gupta R, Syngelaki A, 
Poon LC, Nicolaides KH. First-trimester screening for spontaneous preterm 
delivery with maternal characteristics and cervical length. Fetal Diagn Ther 
2012;31:154-61. 
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The next Chapter will address screening for gestational diabetes mellitus and fetal 
macrosomia at 11-13 weeks’ gestation by a combination of maternal factors, 
biophysical and biochemical markers.  
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CHAPTER 6.  EARLY SCREENING FOR 
GDM AND MACROSOMIA 
 
This chapter is based on two publications. Gestational diabetes mellitus (GDM) 
is associated with increased risk of maternal and perinatal short-term and 
long-term complications. The frequency of adverse pregnancy outcomes can be 
reduced by appropriate treatment of GDM. However, there is no internationally 
accepted method of screening. Fetal macrosomia is associated with increased 
risks for the mother, including caesarean section and trauma to the birth canal, 
and for the baby, including shoulder dystocia and consequent brachial plexus or 
facial nerve injuries, fractures of the humerus or clavicle and birth asphyxia. 
 
In the first paper, we developed a model for the prediction of GDM 
from maternal characteristics and biochemical markers at 11 to 13 weeks' 
gestation in a prospective screening population. In addition, we measured 
maternal serum concentrations of several biomarkers in a case-control study. In 
the second paper, we explored the potential value of the parameters used in 
screening for aneuploidies at 11-13 weeks, combined with maternal 
characteristics, in providing significant prediction of macrosomia. We used 
multiple regression analysis to determine the significant contributors.  
 
 
Publications 
 
http://www.ncbi.nlm.nih.gov/pubmed/21268030 Nanda S, Savvidou M, 
Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes 
mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 
2011;31:135-41.  
 
http://www.ncbi.nlm.nih.gov/pubmed/20798483 Poon LC, Karagiannis G, 
Stratieva V, Syngelaki A, Nicolaides KH. First-trimester prediction of macrosomia. 
Fetal Diagn Ther 2011;29:139-47. 
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The next Chapter summarizes the conclusions of all studies presented in the 
previous Chapters. 
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CHAPTER 7.  CONCLUSIONS 
 
 
 
7.1  Implications for clinical practise  
 
The current approach to prenatal care, which involves visits at 16, 24, 28, 30, 32, 34 
and 36 weeks and then weekly until delivery, was established more than 80 years 
ago (Ballantyne 1921). The high concentration of visits in the third-trimester implies 
that firstly, most complications occur at this late stage of pregnancy and secondly, 
most adverse outcomes are unpredictable during the first- or even the 
second-trimester (Nicolaides 2011a, Nicolaides 2011b). This thesis has presented 
evidence that many pregnancy complications are predictable at an integrated first 
hospital visit at 11-13 weeks combining data from maternal characteristics and 
history with findings of biophysical and biochemical tests. It is therefore proposed 
that the traditional pyramid of care should be inverted with the main emphasis 
placed in the first- rather than the third-trimester of pregnancy (Nicolaides 2011a, 
Nicolaides 2011b). Early estimation of patient-specific risks for pregnancy 
complications will improve pregnancy outcome by shifting prenatal care from a 
series of routine visits to a more individualized patient and disease-specific 
approach.  
 
The role of early pharmacological interventions, in women identified by early 
screening as high risk for pregnancy complications is under investigation. There is 
evidence to suggest that aspirin, starting from the first-trimester can improve 
placentation and reduce the prevalence of preeclampsia. Two recent meta-analyses 
suggested that prophylactic use of low dose aspirin starting in early pregnancy can 
halve the incidence of preeclampsia (Bujold 2010, Roberge 2012). Furthermore, 
regular monitoring of cervical length from the first trimester of pregnancy in women 
beeing at high risk for preterm bith and earlier intervention with measures such as 
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prophylactic use of progesterone or cervical cerclage could improve maternal and 
neonatal outcomes (Fonseca 2007, Berghella 2011). Lastly, effective early 
screening for gestational diabetes mellitus (GDM) may result in early diagnosis and 
treatment of GDM with a significant improvement in perinatal outcomes and 
reduction in associated macrosomia. Furthermore, the high risk group may benefit 
by therapeutic interventions such as probiotic ingestion from early pregnancy (Nitert 
2013). 
 
The papers included in this thesis have been extensively cited in the literature by 
other research groups examining similar research questions. The number of 
citations of these papers and my contribution are presented in the Appendix. The 
major strenght of all these large observational studies included is that we efficiently 
used all available data from a routine antenatal visit in a National Health System 
setting and the results are likely to be generalisable because they include a 
representative sample of the whole pregnant population. 
 
 
7.2 Early screening for aneuploidies 
 
Trisomies 21, 18 and 13 account for about 80% of the detected clinically significant 
chromosomal abnormalities (Syngelaki 2014). First-trimester screening by a 
combination of maternal age, fetal nuchal translucency (NT), fetal heart rate (HRT) 
and serum free β-human chorionic gonadotropin (β-hCG) and 
pregnancy-associated plasma protein (PAPP-A) and the use of risk algorithms for 
trisomy 21, 18 and 13, can detect 90% of fetuses with trisomy 21 and 95% of 
fetuses with trisomies 13 and 18 at a false positive rate (FPR) of 4% (Wright 2014). 
The prevalence of trisomies 21, 18 and 13, monosomy X, triploidy and other 
abnormalities at high-risk of adverse outcome is higher in the group with estimated 
risk for trisomies 21, 18 or 13 of >1:100, compared to those with risk of <1:100, and 
in those with fetal NT >3.5 mm, compared to those with NT<3.5 mm (Syngelaki 
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2014).  
 
The performance of screening for trisomy 21 and trisomy 18 by cell free (cf) DNA 
testing in maternal blood in a routine population is as effective with detection rate 
(DR) >99% and FPR <1% (Nicolaides 2012). If cfDNA testing was offered as a 
first-line method of screening to all pregnancies about 99% of fetuses with trisomy 
21 and 96% with trisomies 13 and 18 could be detected at an overall invasive 
testing rate of 1% (Nicolaides 2014a). In contingent screening, detection of 98% of 
fetuses with trisomy 21 and about 96% of fetuses with trisomies 18 or 13, at an 
overall invasive testing rate of less than 1%, can be achieved by carrying out cfDNA 
testing in about 35%, 20% and 10% of cases identified by first-line screening with 
the combined test alone, the combined test with the addition of serum placenta 
growth factor (PLGF) and alpha-fetoprotein (AFP) and the combined test with the 
addition of PLGF, AFP and ductus venosus pulsatility index for veins (DV PI), 
respectively (Nicolaides 2014a). cfDNA testing contingent on the results of first-line 
screening by ultrasound and biochemical testing would potentially detect most of 
the cases of monosomy X and between half and one third of the few other clinically 
significant chromosomal abnormalities that are currently detected by invasive 
testing if the risk for trisomies 21, 18 or 13 from the combined test is >1:100 
(Syngelaki 2014). 
 
 
7.3 Early screening for fetal defects 
 
At 11-13 weeks’ gestation some abnormalities are always detectable, some can 
never be and others are potentially detectable depending on their association with 
increased NT, the phenotypic expression of the abnormality with gestation and the 
objectives set for such a scan (Syngelaki 2011a). Fetal NT is above the 95th 
percentile in 35% of the fetuses with cardiac defects and in 4.8% of those fetuses 
without cardiac defects (Syngelaki 2011a). Reversed a-wave in the DV is observed 
in 28% of the fetuses with cardiac defects and in 2% of those with no cardiac 
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defects (Cheleman 2011). Specialist fetal echocardiography for cases with NT 
above the 99th percentile and those with reversed a-wave, irrespective of NT, would 
detect 39% of major cardiac defects at an overall FPR of 2.7% (Cheleman 2011). 
Therefore, assessment of ductus venosus flow improves the performance of NT 
screening for cardiac defects (Cheleman 2011).  
 
Tricuspid regurgitation at 11-13 weeks’ gestation is observed in about 1% of normal 
fetuses and in one-third of those with major cardiac defects (Pereira 2011). Fetal NT 
above the 95th percentile, TR or DV reversed a-wave are observed in 35%, 33% 
and 28%, respectively, of the fetuses with cardiac defects and 4.8%, 1.3% and 2.1% 
respectively, of those without cardiac defects. Any one of the three markers is found 
in 58% of the fetuses with cardiac defects and in 8.0% of those without cardiac 
defects (Pereira 2011). Assessment of flow across the tricuspid valve improves the 
performance of screening for major cardiac defects by fetal NT and DV flow (Pereira 
2011). 
 
 
7.4 Early screening for preeclampsia 
 
The prevalence of early, intermediate and late preeclampsia (PE) is 0.3%, 0.6% and 
1.3%, respectively (Akolekar 2011). Algorithms that combine various maternal 
characteristics at 11-13 weeks can potentially identify 33%, 28% and 25% of 
pregnancies that subsequently develop early, intermediate and late PE, at the FPR 
of 5% (Akolekar 2011). Screening by maternal characteristics, uterine artery 
pulsatility index (PI) and mean arterial pressure (MAP) can detect 89% of cases of 
PE requiring delivery before 34 weeks and 56% of all cases of PE, at a fixed FPR of 
10% (Wright 2012). Screening by maternal characteristics, biophysical and 
biochemical markers detected 96% of cases of PE requiring delivery before 34 
weeks and 54% of all cases of PE at fixed FPR of 10% (Akolekar 2013). 
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7.5 Early screening for preterm birth 
 
The rate of spontaneous preterm delivery before 34 weeks in a heterogeneous 
inner city population is 1% (Beta 2011). Patient-specific risk of preterm delivery can 
be provided by maternal factors and obstetric history (Beta 2011). This model can 
detect 38.2% of the preterm deliveries in women with previous pregnancies at or 
beyond 16 weeks and 18.4% in those without, at a FPR of 10%. 
 
First-trimester screening for spontaneous early preterm delivery can be 
substantially improved by the addition of the sonographic measurement of cervical 
length with estimated DR of 54.8% at a FPR of 10% (Greco 2011). 
 
 
7.6 Early screening for gestational diabetes and macrosomia 
 
In screening for gestational diabetes mellitus by maternal characteristics the DR is 
61.6% at a FPR of 20% and the detection increased to 74.1% by the addition of 
adiponectin and sex hormone binding globulin (Nanda 2011). Prediction of 
macrosomia can be provided in the first-trimester of pregnancy by a combination of 
maternal characteristics and measurements of fetal NT, free-βhCG and PAPP-A with 
a DR of 35%, at a FPR of 10% (Poon 2011). 
 
 
7.7 Implementation and implications of screening programme  
 
My papers on fetal aneuploidies have provided strong evidence that screening for 
fetal trisomies is greatly improved by the ultrasound examination of the ductus 
venosus flow as well as the addition of maternal serum analysis of PLGF and AFP. 
The latter can be added to the existing model of screening for trisomy 21 with a 
small additional cost as these are relatively cheap biochemical tests done by 
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automated machines. In contrast, universal examination of the ductus venosus flow 
would require a big relative change to the existing approach, as extensive training 
of the sonographers, an auditing process of this measurement in a national level 
and increase in time of the appointments would be absolutely necessary which will 
result to an increase in the overall cost of screening. 
 
My papers on cfDNA testing for screening for fetal trisomies have demonstrated that 
this is the most effective screening test not only in high risk pregnancies but also in 
a routine low risk population. The integration of cfDNA testing in the current method 
of screening for aneuploidies will not only result in a significant improvement in 
detecting fetal trisomy 21 and but will also substantially reduce the unnecessary 
invasive testing and its adverse consequence of miscarriage especially in the cases 
of normal fetuses. Studies have demonstrated that most mothers would prefer 
cfDNA testing compared to an invasive test, however, the high cost of the test still 
remains an obstacle for the NHS to incorporate it in the current method of 
screening. 
 
My papers have demonstrated that identification of many major fetal structural 
defects is possible at the first trimester of pregnancy. The beneficial consequence of 
this, is that parents can be better prepared in case they wish to continue with the 
pregnancy or offered the option of an earlier and safer termination of pregnancy 
compared to one at the end of the second trimester. The performance, however, for 
most abnormalities to be detected early in pregnancy ultimately depends on a policy 
decision as to the objectives of the first trimester scan and the necessary allocation 
of resources for achieving such objectives. 
 
My papers have demonstrated that preeclampsia, preterm birth and gestational 
diabetes which are major causes of perinatal mortality and morbidity can be 
effectively predicted form the first trimester of pregnancy. Using specific algorithms 
that combine maternal characteristics, biochemical tests, and measurement of 
uterine artery Dopplers and mean arterial pressure, women can be provided an 
CONCULSIONS 
 
54 
 
individual patient-specific risk for these complications from as early as 12 weeks’ 
gestation. At that stage the great majority of women would be classified as being at 
low-risk for pregnancy complications and a small proportion of women would be 
selected as being at high-risk. In the low-risk group the number of medical visits can 
be substantially reduced. One visit at 20-22 weeks will re-evaluate fetal anatomy 
and growth and reassess risk for such complications as preeclampsia and preterm 
delivery. Another visit at 32 or 36 weeks will assess maternal and fetal wellbeing 
and determine the best time and method of delivery and this will be repeated at 41 
weeks for the few that remain pregnant at this stage. The high-risk group can have 
close surveillance in specialist clinics both in terms of the investigations to be 
performed and the personnel involved in the provision of care. In each of these 
visits their risk will be reassessed and they will either remain high-risk or they will 
become low-risk in which case the intensity of their care can be reduced. 
 
The incidence of pregnancy complications has been increasing over the years, 
firstly because of the maternal aging population as well as the dramatic increase of 
maternal obesity, not only in the UK but worldwide. Even though, the existing 
antenatal care allows women to be seen in a regular basis, the adverse 
consequences of pregnancy complications have not been reduced. The proposed 
model of antenatal care arising from my papers emphasizes in the first trimester of 
pregnancy and provides women with a clear direction as to whether their 
pregnancies are high or low risk for subsequent development of most of 
complications. With the view that the high risk group can benefit by prophylactic 
pharmacological interventions the incidence of adverse pregnancy outcomes and 
their consequences can be potentially reduced.   
 
 
7.8 Future direction of research  
 
Since the date of the publications of this thesis, I have continued to research on the 
prediction of pregnancy complications and I have co-authored a series of papers 
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published in peer-review international journals not included in this thesis (Syngelaki 
2015a, Syngelaki 2015b, Akolekar 2015, Wright 2015, Bahado-Singh 2015, 
O'Gorman 2015, James 2015, Nicolaides 2014b, Gil 2014, Nicolaides 2014c, 
Bahado-Singh 2014, David 2014, Ashoor 2013a, Ashoor 2013b, Gallo 2013, 
Nicolaides 2013a, Nicolaides 2013b, Guex 2013, Lai 2013a, Lai 2013b, Llurba 2013, 
Poon 2013, Savvidou 2013, Maiz 2012, Ferreira 2012, Khalil 2012, Pandya 2012, 
Syngelaki 2011b, Staboulidou 2011, Bredaki 2011). These papers are focusing in 
improving the performance of the algorithms in screening for pregnancy 
complications, not only at 12 weeks but also at 22, 32 and 36 weeks’ gestation. 
Furthermore, the algorithms for screening for PE have been the basis of a large 
ongoing multicenter European randomised controlled trial investigating the value of 
screening for PE and treatment of the high-risk group with low-dose aspirin (ASPE 
trial). In addition, we recently published the results of a randomised controlled trial 
investigating the value of cervical pessary in women being at high risk for preterm 
birth (Nicolaides 2015). Lastly, we have just completed and submitted for 
publication the results of another randomised controlled trial investigating the use of 
metformin in reducing adverse maternal and neonatal outcomes from the first 
trimester of pregnancy in non-diabetic women with a body mass index >35kg/m2 
who are in particular high risk for all pregnancy complications.  
 
My focus for the years to come will be to investigate if early diagnosis of gestational 
diabetes mellitus by a glucose tolerance test at 12 weeks’ gestation will improve 
pregnancy outcomes. This will necessitate another randomised controlled trial 
where the control group will have a routine antenatal care and the intervention 
group will have early testing and early treatment.  
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